Latest Articles
Rina-S Wins FDA Breakthrough Therapy Designation for Advanced or Recurrent Endometrial Cancer - OncLive
Rina-S Wins FDA Breakthrough Therapy Designation for Advanced or Recurrent Endometrial Cancer OncLive
Published: Aug. 26, 2025, 3:01 p.m.
Genmab's Rina-S: A Breakthrough in Gynecologic Oncology and a Catalyst for Value Creation - AInvest
Genmab's Rina-S: A Breakthrough in Gynecologic Oncology and a Catalyst for Value Creation AInvest
Published: Aug. 26, 2025, 1:01 p.m.
Why Jemperli and Zejula will be key assets in GSK's India oncology portfolio? - MSN
Why Jemperli and Zejula will be key assets in GSK's India oncology portfolio? MSN
Published: Aug. 26, 2025, 12:50 p.m.
Stanhope Street group serves up support for women facing period poverty - Not Really Here Group
Stanhope Street group serves up support for women facing period poverty Not Really Here Group
Published: Aug. 26, 2025, 12:37 p.m.
Strictly Come Dancing's Anton Du Beke's wild three-word reaction to wife - MSN
Strictly Come Dancing's Anton Du Beke's wild three-word reaction to wife MSN
Published: Aug. 26, 2025, 12:35 p.m.
Why Jemperli and Zejula will be key assets in GSK’s India oncology portfolio? - Business Today
Why Jemperli and Zejula will be key assets in GSK’s India oncology portfolio? Business Today
Published: Aug. 26, 2025, 12:29 p.m.
Dylan Sprouse’s Wife Barbara Palvin Reveals Private Health Battle - PopCulture.com
Dylan Sprouse’s Wife Barbara Palvin Reveals Private Health Battle PopCulture.com
Published: Aug. 26, 2025, 12:07 p.m.
Genmab Receives FDA Breakthrough Therapy Designation for - GlobeNewswire
Genmab Receives FDA Breakthrough Therapy Designation for GlobeNewswire
Published: Aug. 26, 2025, 12:06 p.m.
Genmab Receives FDA Breakthrough Therapy Designation for Rinatabart Sesutecan (Rina-S®) in Advanced Endometrial Cancer (EC) - Yahoo Finance
Genmab Receives FDA Breakthrough Therapy Designation for Rinatabart Sesutecan (Rina-S®) in Advanced Endometrial Cancer (EC) Yahoo Finance
Published: Aug. 26, 2025, noon
Maintenance olaparib after platinum-based chemotherapy for advanced/metastatic endometrial cancer: GINECO randomized phase IIb UTOLA trial - Nature
Maintenance olaparib after platinum-based chemotherapy for advanced/metastatic endometrial cancer: GINECO randomized phase IIb UTOLA trial Nature
Published: Aug. 26, 2025, 11:43 a.m.
Link copied to clipboard!